Why the study?
Does upfront high-dose loop diuretic therapy overcome diuretic resistance in patients with decompensated heart failure?
Does upfront high-dose loop diuretic therapy overcome diuretic resistance in patients with decompensated heart failure?
Answers are grounded in this paper and cite their sources.
This editorial highlights the ongoing debate and need for evidence regarding the optimal starting dose of loop diuretics to overcome diuretic resistance in decompensated heart failure.
This editorial refers to ‘Very high dose loop diuretics for worsening heart failure – a randomized pilot trial, by Y. N. V. Reddy et al., https://doi.org/10.1093/ejhf/xuag069. Loop diuretics remain the cornerstone of decongestive therapy in patients with decompensated heart failure (HF). Despite their widespread use, diuretic resistance occurs in approximately 15–30% of patients and is associated with an increased risk of HF rehospitalization and mortality.1 Although these numbers are well known, limited data inform on the optimal starting dose of loop diuretics. While the DOSE trial demonstrated that high-dose intravenous loop diuretic therapy (2.5 times the outpatient oral dose, Figure 1) was both effective and safe compared to the low-dose strategy (equal to the outpatient oral dose) in terms of symptom relief and weight reduction, in clinical practice, most physicians use loop diuretic doses based on local customs.2 In addition, concerns regarding aggressive decongestion—particularly worsening renal function (WRF)—continue to temper the use of truly high doses in everyday clinical practice. The question remains, however, whether this is merely a perceived risk and if upfront high-dose loop diuretic therapy might, at least in part, overcome the observed diuretic resistance in HF patients.
No takes yet. Share an insight, caveat, or question.
Zonneveld et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: